<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34111579</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-0691</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</Title><ISOAbbreviation>Clin Microbiol Infect</ISOAbbreviation></Journal><ArticleTitle>Post-COVID-19 symptoms 6&#xa0;months after acute infection among hospitalized and non-hospitalized patients.</ArticleTitle><Pagination><StartPage>1507</StartPage><EndPage>1513</EndPage><MedlinePgn>1507-1513</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cmi.2021.05.033</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1198-743X(21)00281-0</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the prevalence of and factors associated with post-coronavirus disease 2019 (COVID-19) syndrome 6&#xa0;months after the onset.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A bidirectional prospective study. Interviews investigated symptoms potentially associated with COVID-19 6&#xa0;months after the disease onset of all consecutive adult inpatients and outpatients with COVID-19 attending Udine Hospital (Italy) from March to May 2020. IgG antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) were also evaluated 6&#xa0;months after the onset of symptoms, at the time of the interview.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 599 individuals were included (320 female, 53.4%; mean age 53&#xa0;years, SD 15.8) and interviewed 187&#xa0;days (22 SD) after onset. The prevalence of post-COVID-19 syndrome was 40.2% (241/599). The presence of IgG antibodies was significantly associated with the occurrence of post-COVID-19 syndrome (OR 2.56, 95% CI 1.48-4.38, p 0.001) and median SARS-CoV-2 IgG titres were significantly higher in patients with post-COVID-19 syndrome than in patients without symptoms (42.1, IQR 17.1-78.4 vs. 29.1, IQR 12.1-54.2 kAU/L, p 0.004). Female gender (OR 1.55, 95% CI 1.05-2.27), a proportional increase in the number of symptoms at the onset of COVID-19 (OR 1.81, 95% CI 1.59-2.05) and ICU admission OR 3.10, 95% CI 1.18-8.11) were all independent risk factors for post-COVID-19 syndrome. The same predictors also emerged in a subgroup of 231 patients with the serological follow-up available at the time of the interview alongside the proportional increase in anti-SARS-CoV-2 IgG (OR 1.01, 95% CI 1.00-1.02, p 0.04).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Prospective follow-up could be offered to specific subgroups of COVID-10 patients, to identify typical symptoms and persistently high anti-SARS-CoV-2 IgG titres as a means of early detection of post-COVID-19 long-term sequelae.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peghin</LastName><ForeName>Maddalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, Department of Medicine, University of Udine, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy. Electronic address: maddalena.peghin@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palese</LastName><ForeName>Alvisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, University of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venturini</LastName><ForeName>Margherita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, University of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Martino</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Medical Statistic, Department of Medicine (DAME), University of Udine, 33100, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerussi</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, Department of Medicine, University of Udine, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graziano</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, Department of Medicine, University of Udine, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bontempo</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, Department of Medicine, University of Udine, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marrella</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, Department of Medicine, University of Udine, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tommasini</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, Italy; University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabris</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Clinical Pathology, Department of Laboratory Medicine, University of Udine, ASUFC, Udine, Italy; Department of Medicine (DAME), University of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curcio</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Clinical Pathology, Department of Laboratory Medicine, University of Udine, ASUFC, Udine, Italy; Department of Medicine (DAME), University of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isola</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Medical Statistic, Department of Medicine (DAME), University of Udine, 33100, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tascini</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, Department of Medicine, University of Udine, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Microbiol Infect</MedlineTA><NlmUniqueID>9516420</NlmUniqueID><ISSNLinking>1198-743X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID survivors</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Chronic COVID</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Patients with post-COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">Post-COVID syndrome</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 antibodies</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 serology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>10</Day><Hour>20</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34111579</ArticleId><ArticleId IdType="pmc">PMC8180450</ArticleId><ArticleId IdType="doi">10.1016/j.cmi.2021.05.033</ArticleId><ArticleId IdType="pii">S1198-743X(21)00281-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goertz Y.M.J., Van Herck M., Delbressine J.M., Vaes A.W., Meys R., Machado F.V.C., et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6:542&#x2013;2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed H., Patel K., Greenwood D.C., Halpin S., Lewthwaite P., Salawu A., et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis. J&#xa0;Rehabil Med. 2020;52</Citation><ArticleIdList><ArticleId IdType="pubmed">32449782</ArticleId></ArticleIdList></Reference><Reference><Citation>Honigsbaum M., Krishnan L. Taking pandemic sequelae seriously: from the Russian influenza to COVID-19 long-haulers. Lancet. 2020;396:1389&#x2013;1391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7550169</ArticleId><ArticleId IdType="pubmed">33058777</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M., Los-Arcos I., Hirsch H.H., Codina G., Monforte V., Bravo C., et al. Community-acquired respiratory viruses are a risk factor for chronic lung allograft dysfunction. Clin Infect Dis. 2019;69:1192&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7797743</ArticleId><ArticleId IdType="pubmed">30561555</ArticleId></ArticleIdList></Reference><Reference><Citation>Amenta E.M., Spallone A., Rodriguez-Barradas M.C., El Sahly H.M., Atmar R.L., Kulkarni P.A. Postacute COVID-19: an overview and approach to classification. Open Forum Infect Dis. 2020;7:ofaa509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665635</ArticleId><ArticleId IdType="pubmed">33403218</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A., Bernabei R., Landi F., Gemelli Against C-P-ACSG Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs L.G., Gourna Paleoudis E., Lesky-Di Bari D., Nyirenda T., Friedman T., Gupta A., et al. Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. PLoS One. 2020;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7732078</ArticleId><ArticleId IdType="pubmed">33306721</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers J.H., III, Howard K., Saretsky T., Clifford S., Hoffmann S., Llorens L., et al. Patient-reported outcome assessments as endpoints in studies in infectious diseases. Clin Infect Dis. 2016;63(Suppl 2):S52&#x2013;S56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006216</ArticleId><ArticleId IdType="pubmed">27481954</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE guideline [NG188] COVID-19 rapid guideline: managing the long-term effects of COVID-19 2020. https://www.nice.org.uk/guidance/ng188. Published: 18 December. 2020</Citation></Reference><Reference><Citation>World Health Organization . 2021. Clinical management of COVID-19: interim guidance.https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 (No. WHO/2019-nCoV/clinical/2021.1) 2021. Available at:</Citation></Reference><Reference><Citation>World Health Organization . 2020. Laboratory testing for coronavirus disease (COVID-19) in suspected human cases interim guidance.https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117 (No. WHO/2019-nCoV/laboratory/2020.2) 2020. Available from:</Citation></Reference><Reference><Citation>Center for Health Security  Serology-based tests for COVID-19 2020. https://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-based-tests-for-COVID-19.html Available at:</Citation></Reference><Reference><Citation>Del Rio C., Collins L.F., Malani P. Long-term health consequences of COVID-19. JAMA. 2020;324(17):1723&#x2013;1724</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8019677</ArticleId><ArticleId IdType="pubmed">33031513</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho-Schneider C., Laurent E., Lemaignen A., Beaufils E., Bourbao-Tournois C., Laribi S., et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021;27(2):258&#x2013;263</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534895</ArticleId><ArticleId IdType="pubmed">33031948</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re&#x2019;em Y., et al. Characterizing Long COVID in an international cohort: 7 months of symptoms and their impact. medRxiv 2020.12.24.20248802. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S., Barnett J., Brill S.E., Brown J.S., Denneny E.K., Hare S.S., et al. Long-COVID&#x2019;: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2020;thoraxjnl-2020-215818</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin S.J., McIvor C., Whyatt G., Adams A., Harvey O., McLean L., et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J&#xa0;Med Virol. 2021;93:1013&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijeratne T., Crewther S. Post-COVID 19 Neurological Syndrome (PCNS); a novel syndrome with challenges for the global neurology community. J&#xa0;Neurol Sci. 2020;419:117179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7550857</ArticleId><ArticleId IdType="pubmed">33070003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciaffi J., Meliconi R., Ruscitti P., Berardicurti O., Giacomelli R., Ursini F. Rheumatic manifestations of COVID-19: a systematic review and meta-analysis. BMC Rheumatol. 2020;4:65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7591274</ArticleId><ArticleId IdType="pubmed">33123675</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhard C., Regitz-Zagrosek V., Neuhauser H.K., Morgan R., Klein S.L. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7247289</ArticleId><ArticleId IdType="pubmed">32450906</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardel A., Wallander M.A., Wallman T., Rosengren A., Johansson S., Eriksson H., et al. Age and sex related self-reported symptoms in a general population across 30 years: patterns of reporting and secular trend. PLoS One. 2019;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6361431</ArticleId><ArticleId IdType="pubmed">30716129</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Kim S.S., Lindsell C.J., Billig Rose E., Shapiro N.I., Files D.C., et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems Network &#x2013; United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:993&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Davido B., Seang S., Tubiana R., de Truchis P. Post-COVID-19 chronic symptoms: a postinfectious entity? Clin Microbiol Infect. 2020;26:1448&#x2013;1449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7376333</ArticleId><ArticleId IdType="pubmed">32712242</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouse B.T., Sehrawat S. Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol. 2010;10:514&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3899649</ArticleId><ArticleId IdType="pubmed">20577268</ArticleId></ArticleIdList></Reference><Reference><Citation>Godfred-Cato S., Bryant B., Leung J., Oster M.E., Conklin L., Abrams J., et al. COVID-19-associated multisystem inflammatory syndrome in children &#x2013; United States, March-July 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1074&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7440126</ArticleId><ArticleId IdType="pubmed">32790663</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao A.T., Tong Y.X., Zhang S. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients. Clin Infect Dis. 2020;71:2249&#x2013;2251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188124</ArticleId><ArticleId IdType="pubmed">32306036</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Geng X., Tan Y., Li Q., Xu C., Xu J., et al. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomed Pharmacother. 2020;127:110195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186209</ArticleId><ArticleId IdType="pubmed">32361161</ArticleId></ArticleIdList></Reference><Reference><Citation>Broderick G., Fuite J., Kreitz A., Vernon S.D., Klimas N., Fletcher M.A. A&#xa0;formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun. 2010;24:1209&#x2013;1217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2939140</ArticleId><ArticleId IdType="pubmed">20447453</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F., et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N&#xa0;Engl J Med. 2020;383:120&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Needham D.M., Davidson J., Cohen H., Hopkins R.O., Weinert C., Wunsch H., et al. Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders' conference. Crit Care Med. 2012;40:502&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">21946660</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi R., Socci V., Talevi D., Mensi S., Niolu C., Pacitti F., et al. COVID-19 pandemic and lockdown measures impact on mental health among the general population in Italy. Front Psychiatr. 2020;11:790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7426501</ArticleId><ArticleId IdType="pubmed">32848952</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi O.L., Calvert M.J. Patient-reported outcomes: central to the management of COVID-19. Lancet. 2020;396:531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7417142</ArticleId><ArticleId IdType="pubmed">32791038</ArticleId></ArticleIdList></Reference><Reference><Citation>Plebani M., Padoan A., Negrini D., Carpinteri B., Sciacovelli L. Diagnostic performances and thresholds: the key to harmonization in serological SARS-CoV-2 assays? Clin Chim Acta. 2020;509:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261100</ArticleId><ArticleId IdType="pubmed">32485157</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association . vol. 10. APA; Washington, DC: 2013. (DSM-5 diagnostic classification).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>